research ▼ Strontium ranelate discontinued
Strontium ranelate is no longer available for treatment.
Search
for
Sort by
Research
420-450 / 1000+ resultsresearch Nitroxide pharmaceutical development for age-related degeneration and disease
Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
research Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED) due to AIRET16M mutation in a consanguineous Greek girl
An 11-year-old Greek girl was diagnosed with a rare genetic disorder, highlighting the importance of genetic testing and family history.
research Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.
research Dual-drug nanostructured lipid carriers of spironolactone and 2-deoxy-D-ribose for targeted follicular delivery in androgenetic alopecia
Nanocarriers with spironolactone and 2-deoxy-D-ribose may improve hair loss treatment by targeting hair follicles directly.
research Ethosomes: New Prospects in Transdermal Delivery
Ethosomes can safely and effectively deliver various drugs deep into the skin.
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research From in-vitro to in-vivo: Corporate development and efficacy of a topical hair growth agent derived from natural extracts
A natural extract-based hair growth product was developed and showed promise in preliminary tests.
research 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
research Targeting integrin pathways: mechanisms and advances in therapy
New therapies are being developed that target integrin pathways to treat various diseases.
research Effects of oxytocin receptor agonists on hair growth promotion
OXTR agonists may promote hair growth and be effective for treating hair loss.
research INTRADERMOTERAPIA CAPILAR: BENEFÍCIOS NO TRATAMENTO DA ALOPECIA
Hair intradermotherapy effectively treats hair loss and boosts self-esteem.
research Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Drug repurposing is a cost-effective way to find new uses for existing drugs, speeding up treatment development.
research Chaotrope-Guided Protein Microneedles with High Drug-Loading Capacity, Ultrafast Dissolution, and High Mechanical Strength
research Can dermal delivery of therapeutics be improved using thermoresponsive nanogels?
Thermoresponsive nanogels show promise for delivering medicine through the skin but need more safety testing and regulatory approval before clinical use.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures
Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.
research Molecular Docking Studies and ADME Prediction of Novel Isatin Analogs with Potent Anti-EGFR Activity
Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia
Suppressing eIF4E can prevent hair loss from chemotherapy.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome
PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
research Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review
Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.
research 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
research Hepato- and neuro-toxicity by ethylenthiourea.
Ethylenthiourea is toxic to the liver and nervous system, especially with alcohol.